HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Germline polymorphism of p53 codon 72 in gynecological cancer.

AbstractOBJECTIVE:
To investigate the biological significance of single nucleotide polymorphism at codon 72 of the p53 gene in the development of gynecological cancer.
METHODS:
p53 codon 72 polymorphism was examined in a total of 354 blood samples from 95 normal, 83 cervical, 108 endometrial and 68 ovarian cancer cases using polymerase chain reaction and restriction fragment length polymorphism techniques.
RESULTS:
When p53 codon 72 genotype was classified into two subgroups of Arg/Arg and Arg/Pro + Pro/Pro, the Arg/Arg genotype was associated with an increased risk for the development of endometrial cancer (OR = 1.86, 95% CI = 1.06 to 3.26) compared with the Arg/Pro + Pro/Pro genotype (P = 0.0301). The Arg allele also increased the risk of endometrial cancer (OR = 1.42, 95% CI = 0.93 to 1.52) compared with the Pro allele, but no statistical difference was found (P = 0.1031). There was no significant difference in the genotype or allele prevalence between control subjects and cervical or ovarian cancer patients.
CONCLUSION:
Homozygous Arg at codon 72 of the p53 gene may be a risk factor for developing endometrial cancer in a Japanese population.
AuthorsMasatsugu Ueda, Yoshito Terai, Koji Kanda, Masanori Kanemura, Mikio Takehara, Hiroyuki Yamaguchi, Koji Nishiyama, Masayuki Yasuda, Minoru Ueki
JournalGynecologic oncology (Gynecol Oncol) Vol. 100 Issue 1 Pg. 173-8 (Jan 2006) ISSN: 0090-8258 [Print] United States
PMID16168468 (Publication Type: Journal Article)
Chemical References
  • Codon
Topics
  • Adult
  • Aged
  • Alleles
  • Codon
  • Female
  • Genes, p53 (genetics)
  • Genital Neoplasms, Female (genetics)
  • Genotype
  • Germ-Line Mutation
  • Humans
  • Middle Aged
  • Polymorphism, Single Nucleotide
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: